Global Generic Central Nervous System Drugs Market Report 2024

Generic Central Nervous System Drugs Global Market Report 2024 – By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types), By Drug Classification (Branded Drugs, Generic Drugs), By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation, Other Route Of Administrations), By Mode Of Purchase (Over-the-counter drugs, Prescription-Based Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033

Generic Central Nervous System Drugs Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : 175 | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Generic Central Nervous System Drugs Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Generic Central Nervous System Drugs Market Definition

Generic central nervous system (CNS) drugs refer to the drugs that have an impact on the central nervous system agents (CNS) by slowing down brain activity. They are used to treat seizures, anxiety, panic attacks, and insomnia.

The major type of generic central nervous system drugs is anti-psychotic, analgesics, anti-parkinson drugs, anesthetics, anti-epileptics, anti-depressants, and others. Antipsychotics, also known as neuroleptics, are a class of medications primarily used to manage symptoms associated with psychotic disorders, such as schizophrenia and bipolar disorder. The drug classification is branded drugs and generic drugs and the route of administration includes oral, intravenous, intranasal/ inhalation, and others and various diseases are neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases, and CNS cancer. The mode of purchase includes over-the-counter drugs, and prescription-based drugs and is distributed by various channels such as hospital pharmacies, retail pharmacies, and others.

Generic Central Nervous System Drugs Market Segmentation

The generic central nervous system drugs market covered in this report is segmented –

1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types

2) By Drug Classification: Branded Drugs, Generic Drugs

3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer

4) By Route Of Administration: Oral, Intravenous, Intranasal/ Inhalation, Other Route Of Administrations

5) By Mode Of Purchase: Over-the-counter drugs, Prescription-Based Drugs

6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Global Generic Central Nervous System Drugs Market Size 2023 to 2028: Graph

Generic Central Nervous System Drugs Market Size 2024 And Growth Rate

The generic central nervous system drugs market size has grown strongly in recent years. It will grow from $83.71 billion in 2023 to $89.47 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to from increasing number of surgeries, strong growth in emerging markets, and increase in pharmaceutical r&d, geriatric population and increased healthcare expenditure.

Generic Central Nervous System Drugs Market Growth Forecast

The generic central nervous system drugs market size is expected to see strong growth in the next few years. It will grow to $117.21 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing government initiatives for mental health awareness, rise in healthcare expenditure, increasing geriatric population and strong pipeline of drugs. Major trends in the forecast period include invest in wearable technology, biomarkers in cns development, modify existing drugs, invest in drug pipeline, use of 3d printing for drug manufacturing and focus on establishing collaborations with research institutions and established companies. player-adopted strategies in the central nervous system drugs market includes acquiring emerging technological companies, expanding brand portfolios through new product launches and expanding business operations in other regions.

Generic Central Nervous System Drugs Market Driver: Rising Incidence Of Mental Health Disorders Fuels Growth In The Generic Central Nervous System (CNS) Drug Market

The increasing incidence of mental health disorders is expected to propel the growth of the generic central nervous system (CNS) drug market going forward. A mental health disorder is a clinically substantial impairment in a person's cognition, emotional regulation, or conduct. It is usually linked to distress or functional impairment in key areas. Generic central nervous system (CNS) drugs play a crucial role in the management of mental health disorders by providing affordable and accessible treatment options. For instance, in November 2022, according to the Health and Social Care Information Centre, a UK-based federal body that offers content, data, and computer systems for experts, physicians, and controllers in the social and healthcare sectors, the proportion of 17- to 19-year-olds with a suspected mental disorder grew from 17.4% in 2021 to 25.7% in 2022. Therefore, the increasing incidence of mental health disorders is driving the generic central nervous system (CNS) drug market.

Generic Central Nervous System Drugs Market Driver: Surging Healthcare Expenditure Drives Expansion Of The Generic Central Nervous System (CNS) Drug Market

The rising healthcare expenditure drives the growth of the generic central nervous system (CNS) drug market in the forecast period. Healthcare expenditure refers to the total amount of resources spent on healthcare goods and services within a specific period. The generic central nervous system (CNS) drug industry benefits from healthcare spending in several ways, including increased accessibility, affordability, and innovation in the drugs used to treat mental health conditions. For instance, according to the Centers for Medicare & Medicaid Services, a US-based federal healthcare agency, average National Health Expenditures (NHE) growth (5.4%) is projected to exceed average GDP growth (4.6%) between 2022 and 2031, resulting in an increase in the health-spending share of GDP from 18.3% in 2021 to 19.6% in 2031. Additionally, in April 2022, according to a report published by the National Association of Chronic Disease Directors (NACDD), a US-based non-profit public health organization dedicated to chronic disease programs, almost 60 percent of adult Americans have at least one chronic disease, and approximately 40% of American adults have multiple chronic conditions (MCC), and this is expected to cost the US economy $2 trillion annually, or $8,600 per person by 2030. Thus, the rising healthcare expenditure will propel the growth of the generic central nervous system (CNS) drug market.

Global Generic Central Nervous System Drugs Market Major Players

Major companies operating in the generic central nervous system drugs market report are Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram

Global Generic Central Nervous System Drugs Market Trend: Innovative Solutions Drive Growth In Generic Central Nervous System Drugs Market

Product innovations have emerged as a key trend gaining popularity in the generic central nervous system drugs market. Major companies operating in the generic central nervous system drugs market are focused on developing innovative products and solutions to strengthen their position in the market. For instance, in December 2021, Intra-Cellular Therapies, Inc. a US-based biopharmaceutical company launched CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate. As a monotherapy or adjunctive therapy with lithium or valproate, CAPLYTA is the only medication approved by the FDA to treat depressive disorders associated with bipolar I or bipolar II. When it comes to weight, cardiometabolic parameters, and extrapyramidal symptoms (disturbances in movement), CAPLYTA has consistently demonstrated a positive profile. Approximately 11 million adults in the United States suffer from bipolar I and bipolar II disorder, serious, highly prevalent mental health conditions marked by recurrent episodes of mania or hypomania interspersed with periods of major depression (bipolar depression). About half of all bipolar disorder patients have either bipolar I disorder or bipolar II disorder.

Global Generic Central Nervous System Drugs Market Trend: Generic Cns Drugs Market Embraces Biosimilar Development For Enhanced Treatment Options

Major companies operating in the generic central nervous system drugs market are focused on developing biosimilars for central nervous system (CNS) conditions. The development and approval of biosimilars for certain biologic drugs used in CNS disorders are becoming a trend, offering more cost-effective alternatives to branded biologics. For instance, in October 2023, Sandoz a Switzerland-based pharmaceutical company launched natalizumab-sztn, the first biosimilar to treat relapsing forms of multiple sclerosis (MS). This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. MS is an autoimmune disease that affects the central nervous system and is chronic and progressive. The majority of disease-affected individuals go through periods of remission and relapse, which negatively impacts their quality of life. The treatment will be contraindicated in patients with progressive multifocal leukoencephalopathy (PML) and in those who previously had PML.

Generic Central Nervous System Drugs Market Merger And Acquisition: Avenue Therapeutics Expands Cns Portfolio With Acquisition Of Baergic Bio

In November 2022, Avenue Therapeutics, a US-based specialty pharmaceutical company, acquired Baergic Bio for an undisclosed amount. This acquisition makes Avenue a pioneer in the creation of medications that address unmet medical needs in the CNS field. Baergic Bio is a US-based biopharmaceutical company dedicated to the creation and marketing of cutting-edge therapies for the management of CNS (central nervous system) diseases.

Regional Analysis For The Global Generic Central Nervous System Drugs Market

North America was the largest region in the generic central nervous system drugs market in 2023. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generic central nervous system drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The generic central nervous system drugs market consists of sales of sedatives, tranquilizers, and hypnotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The generic central nervous system drugs market research report is one of a series of new reports from The Business Research Company that provides generic central nervous system drugs market statistics, including generic central nervous system drugs industry global market size, regional shares, competitors with a generic central nervous system drugs market share, detailed generic central nervous system drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic central nervous system drugs industry. This generic central nervous system drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Generic Central Nervous System Drugs Report Forecast And Analysis
Report AttributeDetails
Market Size Value In 2024 $89.47 billion
Revenue Forecast In 2033 $117.21 billion
Growth Rate CAGR of 7% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal/ Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-the-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Biogen Inc.; Johnson & Johnson; Hoffmann-La Roche Ltd; Novartis AG; UCB; Sanofi; Pfizer Inc.; Merck KGaA; Sumitomo Dainippon Pharma; AbbVie; Recipharm AB; Neuraxpharm; Sun Pharmaceutical limited; Ranbaxy Laboratories; Merz Pharma GmbH & Co. KGaAare; AstraZeneca; Apotex; Gilead Sciences; Bayer; GlaxoSmithKline; Amgen; Abbott Laboratories; Janssen Pharmaceutica; Teva Canada; Accord Healthcare Inc.; Acerus Pharmaceuticals Corporation; Amgen; EMS Pharma; Hypermarcas; Eurofarma; Teuto Brasileiro; Biolab Farmaceutica; Cristalia; União Quimica; Boehringer Ingelheim; Eli Lilly and Company; Adcock Ingram
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Generic Central Nervous System Drugs Market Characteristics

    3. Generic Central Nervous System Drugs Market Trends And Strategies

    4. Generic Central Nervous System Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Generic Central Nervous System Drugs Market Size and Growth

    5.1. Global Generic Central Nervous System Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Generic Central Nervous System Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Generic Central Nervous System Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Generic Central Nervous System Drugs Market Segmentation

    6.1. Global Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Multiple Sclerosis (MS)

    Anti-Psychotic

    Analgesics

    Anti-Parkinson Drugs

    Anesthetics

    Anti-Epileptics

    Anti-Depressants

    Other Types

    6.2. Global Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Neurovascular Diseases

    CNS Trauma

    Mental Health

    Neurodegenerative Diseases

    Infectious Diseases

    CNS Cancer

    6.3. Global Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Intravenous

    Intranasal/ Inhalation

    Other Route Of Administrations

    6.4. Global Generic Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Over-the-counter drugs

    Prescription-Based Drugs

    6.5. Global Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Other Distribution Channels

    7. Generic Central Nervous System Drugs Market Regional And Country Analysis

    7.1. Global Generic Central Nervous System Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Generic Central Nervous System Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Generic Central Nervous System Drugs Market

    8.1. Asia-Pacific Generic Central Nervous System Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Generic Central Nervous System Drugs Market

    9.1. China Generic Central Nervous System Drugs Market Overview

    9.2. China Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Generic Central Nervous System Drugs Market

    10.1. India Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Generic Central Nervous System Drugs Market

    11.1. Japan Generic Central Nervous System Drugs Market Overview

    11.2. Japan Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Generic Central Nervous System Drugs Market

    12.1. Australia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Generic Central Nervous System Drugs Market

    13.1. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Generic Central Nervous System Drugs Market

    14.1. South Korea Generic Central Nervous System Drugs Market Overview

    14.2. South Korea Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Generic Central Nervous System Drugs Market

    15.1. Western Europe Generic Central Nervous System Drugs Market Overview

    15.2. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Generic Central Nervous System Drugs Market

    16.1. UK Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Generic Central Nervous System Drugs Market

    17.1. Germany Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Generic Central Nervous System Drugs Market

    18.1. France Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Generic Central Nervous System Drugs Market

    19.1. Italy Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Generic Central Nervous System Drugs Market

    20.1. Spain Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Generic Central Nervous System Drugs Market

    21.1. Eastern Europe Generic Central Nervous System Drugs Market Overview

    21.2. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Generic Central Nervous System Drugs Market

    22.1. Russia Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Generic Central Nervous System Drugs Market

    23.1. North America Generic Central Nervous System Drugs Market Overview

    23.2. North America Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Generic Central Nervous System Drugs Market

    24.1. USA Generic Central Nervous System Drugs Market Overview

    24.2. USA Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Generic Central Nervous System Drugs Market

    25.1. Canada Generic Central Nervous System Drugs Market Overview

    25.2. Canada Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Generic Central Nervous System Drugs Market

    26.1. South America Generic Central Nervous System Drugs Market Overview

    26.2. South America Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Generic Central Nervous System Drugs Market

    27.1. Brazil Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Generic Central Nervous System Drugs Market

    28.1. Middle East Generic Central Nervous System Drugs Market Overview

    28.2. Middle East Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Generic Central Nervous System Drugs Market

    29.1. Africa Generic Central Nervous System Drugs Market Overview

    29.2. Africa Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Generic Central Nervous System Drugs Market Competitive Landscape And Company Profiles

    30.1. Generic Central Nervous System Drugs Market Competitive Landscape

    30.2. Generic Central Nervous System Drugs Market Company Profiles

    30.2.1. Biogen Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Johnson & Johnson

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Hoffmann-La Roche Ltd

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Novartis AG

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. UCB

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Generic Central Nervous System Drugs Market Other Major And Innovative Companies

    31.1. Sanofi

    31.2. Pfizer Inc.

    31.3. Merck KGaA

    31.4. Sumitomo Dainippon Pharma

    31.5. AbbVie

    31.6. Recipharm AB

    31.7. Neuraxpharm

    31.8. Sun Pharmaceutical limited

    31.9. Ranbaxy Laboratories

    31.10. Merz Pharma GmbH & Co. KGaAare

    31.11. AstraZeneca

    31.12. Apotex

    31.13. Gilead Sciences

    31.14. Bayer

    31.15. GlaxoSmithKline

    32. Global Generic Central Nervous System Drugs Market Competitive Benchmarking

    33. Global Generic Central Nervous System Drugs Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Generic Central Nervous System Drugs Market

    35. Generic Central Nervous System Drugs Market Future Outlook and Potential Analysis

    35.1 Generic Central Nervous System Drugs Market In 2028 - Countries Offering Most New Opportunities

    35.2 Generic Central Nervous System Drugs Market In 2028 - Segments Offering Most New Opportunities

    35.3 Generic Central Nervous System Drugs Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Generic Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Generic Central Nervous System Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Generic Central Nervous System Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: Biogen Inc. Financial Performance
  • Table 77: Johnson & Johnson Financial Performance
  • Table 78: Hoffmann-La Roche Ltd Financial Performance
  • Table 79: Novartis AG Financial Performance
  • Table 80: UCB Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Generic Central Nervous System Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Generic Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Generic Central Nervous System Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Generic Central Nervous System Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Generic Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Generic Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Generic Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: Biogen Inc. Financial Performance
  • Figure 77: Johnson & Johnson Financial Performance
  • Figure 78: Hoffmann-La Roche Ltd Financial Performance
  • Figure 79: Novartis AG Financial Performance
  • Figure 80: UCB Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the generic central nervous system drugs market?

Generic central nervous system (CNS) drugs refer to the drugs that have an impact on the central nervous system agents (CNS) by slowing down brain activity. They are used to treat seizures, anxiety, panic attacks, and insomnia. For further insights on the generic central nervous system drugs market, request a sample here

How will the generic central nervous system drugs market drivers and restraints affect the generic central nervous system drugs market dynamics? What forces will shape the generic central nervous system drugs industry going forward?

The generic central nervous system drugs market major growth driver - Rising Incidence Of Mental Health Disorders Fuels Growth In The Generic Central Nervous System (CNS) Drug Market. For further insights on the generic central nervous system drugs market, request a sample here

What is the forecast market size or the forecast market value of the generic central nervous system drugs market?

The generic central nervous system drugs market size has grown strongly in recent years. It will grow from $83.71 billion in 2023 to $89.47 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to from increasing number of surgeries, strong growth in emerging markets, and increase in pharmaceutical r&d, geriatric population and increased healthcare expenditure. The generic central nervous system drugs market size is expected to see strong growth in the next few years. It will grow to $117.21 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing government initiatives for mental health awareness, rise in healthcare expenditure, increasing geriatric population and strong pipeline of drugs. Major trends in the forecast period include invest in wearable technology, biomarkers in cns development, modify existing drugs, invest in drug pipeline, use of 3d printing for drug manufacturing and focus on establishing collaborations with research institutions and established companies. player-adopted strategies in the central nervous system drugs market includes acquiring emerging technological companies, expanding brand portfolios through new product launches and expanding business operations in other regions. For further insights on the generic central nervous system drugs market, request a sample here

How is the generic central nervous system drugs market segmented?

The generic central nervous system drugs market is segmented
1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal/ Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-the-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution ChannelsFor further insights on the generic central nervous system drugs market,
request a sample here

Which region has the largest share of the generic central nervous system drugs market? What are the other regions covered in the report?

North America was the largest region in the generic central nervous system drugs market in 2023. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the generic central nervous system drugs market, request a sample here.

Who are the major players in the generic central nervous system drugs market?

Major companies operating in the generic central nervous system drugs market report are Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram For further insights on the generic central nervous system drugs market, request a sample here.

What are the key trends in the generic central nervous system drugs market?

Major trend in the generic central nervous system drugs market - Innovative Solutions Drive Growth In Generic Central Nervous System Drugs Market. For further insights on the generic central nervous system drugs market, request a sample here.

What are the major opportunities in the generic central nervous system drugs market? What are the strategies for the generic central nervous system drugs market?

For detailed insights on the major opportunities and strategies in the generic central nervous system drugs market, request a sample here.

How does the generic central nervous system drugs market relate to the overall economy and other similar markets?

For detailed insights on generic central nervous system drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the generic central nervous system drugs industry?

For detailed insights on the mergers and acquisitions in the generic central nervous system drugs industry, request a sample here.

What are the key dynamics influencing the generic central nervous system drugs market growth? SWOT analysis of the generic central nervous system drugs market.

For detailed insights on the key dynamics influencing the generic central nervous system drugs market growth and SWOT analysis of the generic central nervous system drugs industry, request a sample here.